Covance (NYSE:CVD) last announced its earnings results. The company reported $0.90 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.90. The company had revenue of $620.10 million for the quarter, compared to the consensus estimate of $632.01 million. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. Analysts expect that Covance will post $3.86 EPS for the current fiscal year. Covance Inc. (NYSE:CVD) shares after opening at $84.27 moved to $84.55 on last trade day and at the end of the day closed at $81.91. Company price to sales ratio in past twelve months was calculated as 1.81 and price to cash ratio as 6.43. Covance Inc. (NYSE:CVD) showed a negative weekly performance of -11.89%.
AMN Healthcare Services (NYSE:AHS) had its buy rating reaffirmed by analysts at Citigroup Inc..The firm currently has a $17.00 target price on the stock. AMN Healthcare Services, Inc. (NYSE:AHS) shares fell -10.71% in last trading session and ended the day on $11.25. AHS return on equity ratio is recorded as 15.60% and its return on assets is 5.80%. AMN Healthcare Services, Inc. (NYSE:AHS) yearly performance is -11.83%.
Cambrex Corp. (NYSE:CBM) fell 6.5% during trading on Friday after the company announced weaker than expected quarterly earnings, Analyst Ratings.Net reports. The company traded as low as $17.36 and last traded at $19.33, with a volume of 696,394 shares trading hands. The stock had previously closed at $20.68.The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.16. The company had revenue of $66.20 million for the quarter, compared to the consensus estimate of $79.40 million. Cambrex Corporation (NYSE:CBM) shares moved down -7.01% in last trading session and was closed at $19.23, while trading in range of $ 17.36 – 19.50. Cambrex Corporation (NYSE:CBM) year to date (YTD) performance is 7.85%.
Puma Biotechnology Inc. (NYSE:PBYI) is currently above its 200 day moving average which is currently at $75.98. The momentum indicators for the stocks are indicating further bearishness, and we might see lower levels. We would suggest traders to go short only if the 200 day moving average is breached for targets of $60 in the short term and keeping a stop loss just above the 200 day moving average at $78.Positional traders can short the stock at current levels for targets of $70.86 and if the level of $70.86 is broken we can easily see levels of $65. Puma Biotechnology Inc (NYSE:PBYI) weekly performance is 4.68%. On last trading day company shares ended up $74.64. Puma Biotechnology Inc (NYSE:PBYI) distance from 50-day simple moving average (SMA50) is -26.56%. Analysts mean target price for the company is $130.67.